Key Factors That Guide Myeloma Treatment Decisions
Link to Full Transcript: https://bit.ly/3bEZOVI
Treatment for myeloma varies from one patient to the next. Dr. Joshua Richter, a myeloma specialist, reviews the factors that are considered when choosing a treatment approach.
Dr. Joshua Richter is director of Multiple Myeloma at the Blavatnik Family – Chelsea Medical Center at Mount Sinai. Dr. Richter also serves as Assistant Professor of Medicine in The Tisch Cancer Institute, Division of Hematology and Medical Oncology. Learn more about Dr. Richter, here: https://www.mountsinai.org/profiles/joshua-richter.
Patient Empowerment Network (PEN) is a 501(c)(3) non-profit organization. PEN’s mission is to fortify cancer patients and care partners with the knowledge and tools to boost their confidence, put them in control of their healthcare journey, and assist them in receiving the best, most personalized care available to ensure they have the best possible outcome. Subscribe now to receive the latest news on cancer treatment and research: https://powerfulpatients.org/connect
source
Disclaimer: This content including advice provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information.
Keywords: Dr. Joshua Richter,Blavatnik Family – Chelsea Medical Center at Mount Sinai,hematology,Multiple myeloma,myeloma,relapsed,refractory,CAR T-cell therapy,treatment decisions,combination therapy,myeloma therapy,treatment goals,multiple myeloma treatment,myeloma treatment,peripheral neuropathy,fatigue,translocation 11;14,CARTITUDE-1 Study,ciltacabtagene autoleucel,cilta-cel,BCMA,chimeric antigen receptor T-cell,venclexta,Revlimid,lenalidomide,venetoclax